Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-730-3 | CAS number: -
Carcinogenicity
Administrative data
Description of key information
In view of the absence of genotoxic effects (in vitro and in vivo) and absence of carcinogenic effects in the oral and dermal repeated dose toxicity studies, no carcinogenicity is anticipated.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The information available is adequate for this dossier.
Justification for classification or non-classification
Based on the negative result of all genotoxicity tests OTNE does not need to be classified for genotoxicity according to the EU CLP (EC 1272/2008 and its amendments). In view of the absence of genotoxic effects (in vitro and in vivo) and absence of carcinogenic effects in the repeated dose toxicity studies, no carcinogenicity is anticipated.
Additional information
The genotoxicity of the substance has been assessed in vitro for three genotoxicity endpoints: genotoxicity in bacteria, cytogenicity in a chromosomal aberration test and a gene mutation assay in mammalian cells, which were all negative. Also, two in vivo micronucleus tests are available as part of the 90-day dermal toxicity study (NTP, 2016). No increases in micronuclei were seen in rats (both sexes) and in male mice. The effects seen in female mice at 1000 and 2000 mg/kg bw are difficult to judge. At 2000 mg/kg bw positive results were seen. This dose is however twice the limit dose for a micronucleus test in a repeated dose toxicity study and in the presence of haematological toxic effects and therefore not taken into account. At the 1000 mg/kg bw a minimal increase in micronuclei is seen, which cannot be assessed in absence of (historical) control values. For females it can be concluded that up to 500 mg/kg bw no increase in micronuclei is seen.
In addition, in the subchronic oral toxicity study (Triskelion, 2017) no carcinogenic effects or neoplasms were observed. Additionally, no neoplasms were observed in the supporting sub-chronic dermal (with oral exposure) NTP studies (NTP, 2016).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
